Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...

TOKYO -- The leader of Japanese opposition party Reiwa Shinsengumi, Taro Yamamoto, 51, announced on the party's YouTube ...

The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

CLEVELAND, Ohio — Seven in 10 people now survive their cancer five years or longer, up from only half in the mid-1970s, ...

By a News Reporter-Staff News Editor at Stem Cell Daily-- Investigators publish new report on Oncology- Multiple Myeloma. Our ...

year survival rates averaged across all cancers have never been higher, with 7-in-10 cancer patients living past 5 years post-diagnosis.

Since then Ross Esparza has “perplexed the medical community with unexplained lesions, masses, blood work and biopsies,” said ...

The 5-year relative survival rate for all cancers continued to increase in the US in recent years with prevention and treatment improvements.

GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...

CARY, NC, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- The CEO Roundtable on Cancer (CEORT) today announced ...